



deltaDOT Ltd

LBIC
2 Royal College Street
London
NW1 0NH
UK
<http://www.deltadot.com>

Registered in England No. 3949707

Release date: Monday 14th December 2015

deltaDOT technology has been used to define product quality for ImmBio Ltd

deltaDOT Ltd (London) are pleased to announce that its Label Free Intrinsic Imaging (LFII®) technology has been used to help ImmBio (Cambridge UK) to submit an Investigational Medicinal Product Dossier (IMPD) as part of a clinical trial application to The Medicines and Healthcare products Regulatory Agency (MHRA).

“deltaDOT’s HPCE-512 analytical platform allows rapid quality control assessments and impurity identification” commented deltaDOT’s CSO, Dr Stuart Hassard. “deltaDOT are pleased to have helped ImmBio again in their innovative vaccine development and regulatory interactions”.

Dr Chris Bailey, Development Director at ImmBio added “deltaDOT’s equipment helped us define important quality parameters of our pneumococcal vaccine candidate that has now entered Phase 1 clinical testing. We have been pleased to find an analytical solutions provider in deltaDOT who are able back up their technology with further interactions and insights on the data they generate”

Notes to editors:

ImmBio (Immunobiology Ltd), a biopharmaceutical company developing innovative vaccines against serious infectious diseases. Located at the Babraham Institute, a unit of the UK’s Biotechnology & Biological Sciences Research Council, ImmBio was founded based on advances in understanding of the immune system, in particular the key role of the dendritic cell (DC), which presents breakthrough opportunities to prevent infection. ImmBio utilises two distinct technology platforms, ImmBioVax™ and ImmunoBodies™ to target antigens to DCs. The lead platform, ImmBioVax, mimics normal immune responses to a pathogen utilising multi-protein complexes to elicit priming of the immune system. ImmBio’s unique technologies have the following benefits:

- Eliciting a powerful and long-lasting immune response
- Providing broad immunity, effective against multiple pathogen strains and in diverse human populations
- Emulating normal immune responses to pathogens to optimise the safety profile
- Providing low cost of goods and a clear regulatory pathway to market

Find out more at <http://www.immbio.com>

About deltaDOT Ltd

deltaDOT has developed and commercialised highly innovative Biotechnology instrumentation. The analytical technology is based on an innovative approach to Capillary Electrophoresis (CE). deltaDOT’s patented multipoint sensor system together with the proprietary computing algorithms gives superior resolution, accuracy and repeatability.

This is High Performance Capillary Electrophoresis (HPCE) at its best - Label Free Intrinsic Imaging (LFII®).

This technology has found successful applications in detection, separation and analysis of proteins, nucleic acids, carbohydrates, viruses and bacteria, drugs, chemicals and a wide range of other analytes.

Find out more about deltaDOT Ltd at <http://www.deltadot.com>